John F Dickerson1, Frances L Lynch2, Michael C Leo2, Lynn L DeBar3, John Pearson2, Gregory N Clarke2. 1. Kaiser Permanente Center for Health Research, Portland, Oregon; and john.f.dickerson@kpchr.org. 2. Kaiser Permanente Center for Health Research, Portland, Oregon; and. 3. Kaiser Permanente Washington Health Research Institute, Seattle, Washington.
Abstract
BACKGROUND AND OBJECTIVES:Adolescents with depression identified in primary care settings often have limited treatment options beyond antidepressant (AD) therapy. We assessed the cost-effectiveness of a brief cognitive behavioral therapy (CBT) program among depressed adolescents who declined or quickly stopped using ADs. METHODS: A total of 212 youth with depression were randomly assigned to treatment as usual (TAU) or TAU plus brief individual CBT. Clinical outcomes included depression-free days (DFDs) and estimated quality-adjusted life-years (QALYs). Costs were adjusted to 2008 US dollars. Incremental cost-effectiveness ratios (ICERs) comparing CBT to TAU were calculated over 12- and 24-month follow-up periods. RESULTS: Youth randomly assigned to CBT had 26.8 more DFDs (P = .044) and 0.067 more QALYs (P = .044) on average compared with TAU over 12 months. Total costs were $4976 less (P = .025) by the end of the 24-month follow-up among youth randomly assigned to CBT. Total costs per DFD were -$51 (ICER = -$51; 95% confidence interval [CI]: -$394 to $9) at 12 months and -$115 (ICER = -$115; 95% CI: -$1090 to -$6) at 24 months. Total costs per QALY were -$20 282 (ICER = -$20282; 95% CI: -$156 741 to $3617) at 12 months and -$45 792 (ICER = -$45 792; 95% CI: -$440 991 to -$2731) at 24 months. CONCLUSIONS: Brief primary care CBT among youth declining AD therapy is cost-effective by widely accepted standards in depression treatment. CBT becomes dominant over TAU over time, as revealed by a statistically significant cost offset at the end of the 2-year follow-up.
RCT Entities:
BACKGROUND AND OBJECTIVES: Adolescents with depression identified in primary care settings often have limited treatment options beyond antidepressant (AD) therapy. We assessed the cost-effectiveness of a brief cognitive behavioral therapy (CBT) program among depressed adolescents who declined or quickly stopped using ADs. METHODS: A total of 212 youth with depression were randomly assigned to treatment as usual (TAU) or TAU plus brief individual CBT. Clinical outcomes included depression-free days (DFDs) and estimated quality-adjusted life-years (QALYs). Costs were adjusted to 2008 US dollars. Incremental cost-effectiveness ratios (ICERs) comparing CBT to TAU were calculated over 12- and 24-month follow-up periods. RESULTS: Youth randomly assigned to CBT had 26.8 more DFDs (P = .044) and 0.067 more QALYs (P = .044) on average compared with TAU over 12 months. Total costs were $4976 less (P = .025) by the end of the 24-month follow-up among youth randomly assigned to CBT. Total costs per DFD were -$51 (ICER = -$51; 95% confidence interval [CI]: -$394 to $9) at 12 months and -$115 (ICER = -$115; 95% CI: -$1090 to -$6) at 24 months. Total costs per QALY were -$20 282 (ICER = -$20 282; 95% CI: -$156 741 to $3617) at 12 months and -$45 792 (ICER = -$45 792; 95% CI: -$440 991 to -$2731) at 24 months. CONCLUSIONS: Brief primary care CBT among youth declining AD therapy is cost-effective by widely accepted standards in depression treatment. CBT becomes dominant over TAU over time, as revealed by a statistically significant cost offset at the end of the 2-year follow-up.
Authors: E R Berndt; L M Koran; S N Finkelstein; A J Gelenberg; S G Kornstein; I M Miller; M E Thase; G A Trapp; M B Keller Journal: Am J Psychiatry Date: 2000-06 Impact factor: 18.112
Authors: S Byford; B Barrett; C Roberts; P Wilkinson; B Dubicka; R G Kelvin; L White; C Ford; S Breen; I Goodyer Journal: Br J Psychiatry Date: 2007-12 Impact factor: 9.319
Authors: Frances L Lynch; Mark Hornbrook; Gregory N Clarke; Nancy Perrin; Michael R Polen; Elizabeth O'Connor; John Dickerson Journal: Arch Gen Psychiatry Date: 2005-11
Authors: Frances L Lynch; John F Dickerson; Greg Clarke; Benedetto Vitiello; Giovanna Porta; Karen D Wagner; Graham Emslie; Joan Rosenbaum Asarnow; Martin B Keller; Boris Birmaher; Neal D Ryan; Betsy Kennard; Taryn Mayes; Lynn DeBar; James T McCracken; Michael Strober; Robert L Suddath; Anthony Spirito; Matthew Onorato; Jamie Zelazny; Satish Iyengar; David Brent Journal: Arch Gen Psychiatry Date: 2011-03
Authors: Marisa Elena Domino; Barbara J Burns; Susan G Silva; Christopher J Kratochvil; Benedetto Vitiello; Mark A Reinecke; Jeremy Mario; John S March Journal: Am J Psychiatry Date: 2008-04-15 Impact factor: 18.112
Authors: Dawn M Johnson; Golfo Tzilos Wernette; Ted R Miller; Maria Muzik; Christina A Raker; Caron Zlotnick Journal: Contemp Clin Trials Date: 2020-04-17 Impact factor: 2.226
Authors: Rasmus Trap Wolf; Pia Jeppesen; Mette Maria Agner Pedersen; Louise Berg Puggaard; Mikael Thastum; Niels Bilenberg; Per Hove Thomsen; Wendy K Silverman; Kerstin Jessica Plessen; Simon-Peter Neumer; Christoph U Correll; Anne Katrine Pagsberg; Dorte Gyrd-Hansen Journal: BMC Health Serv Res Date: 2022-06-24 Impact factor: 2.908
Authors: Frances L Lynch; John F Dickerson; Michelle S Rozenman; Araceli Gonzalez; Karen T G Schwartz; Giovanna Porta; Maureen O'Keeffe-Rosetti; David Brent; V Robin Weersing Journal: JAMA Netw Open Date: 2021-03-01